Namur (Belgium), 5 April 2023 Can phage therapy be a realistic alternative to fight antibiotic resistance in production animals? Join us on Wednesday, April 5, starting at 9:30 am at…
read moreNamur (Belgium), 13 January 2023 Vésale Bioscience is developing innovative precision phage therapy solutions to treat bacterial infections resistant to antibiotics, and today announces that it has received a €1.8…
read moreBiosaxony, the Saxony’s Biotechnology, Medical Technology & Health Economy Cluster in Leipzig, has selected Vésale Bioscience for their MEDICAL FORGE Accelerator program 2023 (
read moreCMO Dr Vincent Grek joins Vésale Bioscience as Chief Medical Officer He has a Strong Clinical Development Expertise in the biotech, nutrition and pharmaceutical industry (antibiotics, gene therapy, enzyme replacement…
read moreGunther Vanwezer joins the Vésale Bioscience team as Chief Executive Officer. He hold a Master degree in Biochemical Engineering Technology from the University of Leuven (Belgium). He has over 25…
read moreVésale Bioscience announces that it has been awarded the prize for most innovative start-up in life sciences in Europe during the tenth edition of BioFIT, which was held digitally from…
read moreGérald de Patoul joins the Vésale Bioscience team as Chief Business Development Officer. He co-founded of Oncomfort in May 2017 and acted for 4 years as Director and CFO, in…
read moreVisit of Mr David Clarinval, Minister for the Middle Classes, the Self-Employed, SMEs, Agriculture, Institutional Reforms & Democratic Renewal. The minister met with Vésale Bioscience Executive Team to discuss how…
read morePhilippe Ghem joins the Vésale Bioscience team as Chief Commercial Officer (CCO). Philippe is a commercial Engineer from the Solvay Business School (Brussels) and he brings 30 years of sales…
read more
